This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Epoetin Zeta, as permitted under Section 130a, Paragraph 8 of the German Social Code (SGB V). The GWQ ServicePlus AG, acting on behalf of health insurance companies, is seeking to
Contract awarded. Originally published 1 years ago.
This contract aims to establish selective discount agreements with pharmaceutical companies for the supply of finished medicinal products. These agreements will be based on active ingredients and are divided into specific lots. Detailed information can be found in the contract terms and pricing shee
This contract opportunity involves the establishment of non-exclusive discount agreements for the pharmaceutical product Abiraterone, specifically in the 500mg strength and 90 tablet pack size. Under § 130a Abs. 8 SGB V, health insurance funds and pharmaceutical companies can enter into framework di
This contract opportunity involves the provision of pharmaceutical billing data from mail-order pharmacies, public pharmacies, and outpatient hospital services, along with the delivery of an online analysis software. Suppliers are invited to submit proposals for the supply of these services, which a
This contract pertains to the procurement of the medicine Emcitate, as part of a framework discount agreement between health insurance companies and pharmaceutical companies. The GWQ ServicePlus AG, acting on behalf of its shareholder and client health insurance funds, is conducting a formal procure
Supply non-clinical consumables including forms, labels, and packaging for pathology and primary care services.
Procurement of RSV immunisation vaccine products for adult populations, scheduled for 2028.
Procurement for meningococcal ACWY vaccine supply in 2027 from qualified manufacturers or distributors.
Procurement opportunity for MMR vaccine supply with anticipated delivery timeline of 2027.
